Earnings.com: Event Calendar

TICKER

NAME

Omeros Corporation

PRESS RELEASES

RECENT FINANCIAL NEWS

Back to Directory

Recent News

TITLE	DATE
Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs	30-Nov-2011
Omeros Announces Submission to European Medicines Agency of Paediatric Investigation Plan Letter of Intent for OMS302	29-Nov-2011
Omeros to Present at 23rd Annual Piper Jaffray Health Care Conference	22-Nov-2011
Omeros Corporation Reports Third Quarter 2011 Financial Results	8-Nov-2011
Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302	11-Oct-2011
Omeros Unlocks Four Additional Orphan GPCRs	13-Sep-2011
Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference	6-Sep-2011
Omeros Corporation Reports Second Quarter 2011 Financial Results	9-Aug-2011
Omeros to Present at Two Upcoming Conferences	3-Aug-2011
Omeros Announces Publication of Phase 2 Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery	29-Jun-2011
Omeros Unlocks Orphan GPCRs Linked to Leukemia and Sleep Disorders	27-Jun-2011
Omeros to Present at the Jefferies 2011 Global Healthcare Conference	2-Jun-2011
Omeros Unlocks Orphan GPCR Family Linked to Metabolic and Psychotic Disorders	31-May-2011
Omeros Reports Allowance of Additional Patent for Arthroscopic Product	24-May-2011
Omeros Announces Clinical Development Programs for OMS103HP and OMS302	19-May-2011
Omeros Corporation Reports First Quarter 2011 Financial Results	10-May-2011
Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors	5-May-2011
Omeros to Present at Deutsche Bank Health Care Conference	27-Apr-2011
Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences	19-Apr-2011
Omeros to Present at Future Leaders in the Biotech Industry Conference	11-Apr-2011
Omeros Announces Publication of Data From its PPAR-gamma Addiction Program	7-Apr-2011
Omeros to Present at Needham Healthcare Conference	4-Apr-2011
Omeros Reports Outcome of Phase 3 Trials of OMS103HP	31-Mar-2011
Omeros' Ophthalmology Product OMS302 Achieves Co-Primary Endpoints in Phase 2b Clinical Study	23-Mar-2011
Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results	15-Mar-2011
Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders	2-Mar-2011
Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo	22-Feb-2011
Omeros Announces Publication of Data From Antifibrinolytic Program	10-Feb-2011
Omeros Announces Eligibility of OMS103HP for EMA Centralized Marketing Application	1-Feb-2011
Omeros Licenses Novel Antifibrinolytic Agents	5-Jan-2011
Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy	29-Dec-2010
Omeros to Present at Piper Jaffray Health Care Conference	24-Nov-2010
Omeros Announces Completion of Acquisition of Assay for GPCR Program	23-Nov-2010
Omeros Names Dr. Kenneth Ferguson as Vice President, Development	17-Nov-2010
Omeros Identifies Orphan GPCR-Targeting Compound Potentiating Chemotherapeutic Activity	9-Nov-2010
Omeros Corporation Reports Third Quarter 2010 Financial Results	4-Nov-2010
Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program	3-Nov-2010
Omeros Receives $20 Million from Vulcan Capital and $5 Million Grant Award from Washington State's Life Sciences Discovery Fund to Advance its GPCR Program	25-Oct-2010
Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update	22-Oct-2010
Omeros to Present at the BioCentury NewsMakers Conference	15-Oct-2010
Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program	14-Oct-2010
Omeros to Present at the Rodman & Renshaw Global Investment Conference	8-Sep-2010
Omeros Reports Second Quarter 2010 Financial Results	10-Aug-2010
Omeros to Webcast Presentation at Canaccord Genuity 30th Annual Growth Conference	5-Aug-2010
Omeros Secures $40 Million Committed Equity Financing Facility	29-Jul-2010
Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery	27-Jul-2010
Omeros Successfully Unlocks Orphan GPCRs	29-Jun-2010
Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference	3-Jun-2010
Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders	13-May-2010
Omeros Reports First Quarter 2010 Financial Results	12-May-2010
Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery	3-May-2010
Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference	29-Apr-2010
Omeros Corporation Reports Fourth Quarter and Year-End 2009 Financial Results	31-Mar-2010
Omeros Reports Phase 2 Data Showing Multiple Clinical Benefits in Patients Undergoing Arthroscopic Meniscectomy Surgery	31-Mar-2010
Omeros Corporation to Host Conference Call on Fourth Quarter and Full Year 2009 Results on March 31	15-Mar-2010
Omeros Licenses PDE7 Compounds for Parkinson's Disease Program	9-Mar-2010
Omeros Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program	28-Jan-2010
Daniel K. Spiegelman Elected to Board of Directors of Omeros	9-Dec-2009
Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights	19-Nov-2009
Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19	13-Nov-2009
Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share	7-Oct-2009
Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery	11-Aug-2009
Omeros Appoints New Vice President of Clinical Development	5-Aug-2009
Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program	28-Jan-2009
Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target	6-Jan-2009
Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery	9-Dec-2008
Omeros and BlueCrest Announce $20 Million Debt Facility	24-Sep-2008
Omeros and The Parkinson's Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders	17-Sep-2008
Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302	9-Sep-2008
Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery	26-Aug-2008
Affitech and Omeros Enter Into Antibody Discovery and Development Agreement	19-Aug-2008
Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study	20-May-2008
Omeros Raises More Than $63 Million in Financing	12-Feb-2007
Omeros receives up to $9 million toward development of schizophrenia treatment	9-Jan-2007
Omeros Acquires Nura	7-Sep-2006